Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 6 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  2. US 12115216

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  3. US 12110343

    Anti-plasma kallikrein antibodies

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  4. US 12098118

    Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

    Regents of the University of Minnesota · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  5. US 12097199

    Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  6. US 12091449

    Anti-PfRH5 antibodies and antigen-binding fragments thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  7. US 12084516

    Anti-C5 antibody combinations and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  8. US 12084514

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  9. US 12084504

    Anti-MET antibodies and uses thereof

    AGOMAB THERAPEUTICS · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  10. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  11. US 12077570

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  12. US 12077587

    Anti-CD8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  13. US 12070594

    Biomedical electrode with anti-microbial properties

    COMPASS HEALTH BRANDS CORP. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  14. US 12071436

    Anti-parasitic compounds and uses thereof

    The Regents of the University of California · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  15. US 12071477

    Anti-folate receptor alpha antibody conjugated with hemiasterlins

    Sutro Biopharma, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  16. US 12065506

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  17. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Cell Design Labs, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  18. US 12068729

    Anti-factor XII/XIIa antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  19. US 12065493

    Anti-MICA/B antibodies that block MICA/B shedding and methods of use

    Cullinan Mica Corporation · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  20. US 12065428

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  21. US 12064512

    Silyl lipids suitable for enhanced delivery of anti-viral therapeutics

    The Regents of the University of California · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  22. US 12060428

    Anti-IL36R antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  23. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  24. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted